A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia

BACKGROUND: We compared the time to discontinuation due to lack of tolerability over 24 weeks in patients suffering from schizophrenia treated with pomaglumetad methionil (LY2140023 monohydrate, the prodrug of metabotropic glutamate 2/3 receptor agonist, LY404039) or standard of care (SOC: olanzapin...

Descripción completa

Detalles Bibliográficos
Autores principales: Adams, David H, Kinon, Bruce J, Baygani, Simin, Millen, Brian A, Velona, Isabella, Kollack-Walker, Sara, Walling, David P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666887/
https://www.ncbi.nlm.nih.gov/pubmed/23694720
http://dx.doi.org/10.1186/1471-244X-13-143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666887/
https://www.ncbi.nlm.nih.gov/pubmed/23694720
http://dx.doi.org/10.1186/1471-244X-13-143

Ejemplares similares